CA125糖基异构体在高级别浆液性卵巢癌监测与随访中的纵向分析
本研究对122例高级别浆液性卵巢癌(HGSC)患者进行纵向血清CA125、CA125-STn和CA125-MGL检测,并与肿瘤负荷、残留病灶、治疗反应和无进展生存期等终点比较。结果显示CA125-STn在区分肿瘤负荷、预测完全减灭和提前检测复发方面优于传统CA125,有望成为HGSC监测和随访的有用生物标志物。
要点
- CA125-STn可区分低与高肿瘤负荷,并预测完全减灭。
- CA125-STn最低值可预测无进展生存期。
核心结论
- CA125-STn在HGSC监测和随访中显示出作为有用生物标志物的前景。
研究设计与样本
- 队列研究纳入122例HGSC患者,纵向收集诊断、治疗和随访期血清,检测CA125、CA125-STn和CA125-MGL水平并与临床终点比较。
主要发现
- CA125-STn最低值可预测无进展生存期。
临床怎么用
- CA125-STn可作为HGSC治疗监测和随访的候选生物标志物,辅助评估肿瘤负荷和减灭可能性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Cancer antigen 125 (CA125) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CA125 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. METHODS: Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CA125-STn and CA125-MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). RESULTS: Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. CONCLUSIONS: CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies.
引用
- Salminen L, Nadeem N, Jain S, et al. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. Gynecol Oncol. 2019. PMID: 31889528. doi:10.1016/j.ygyno.2019.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。